A LinkedIn post from Neuromod Devices Ltd describes how partner Specialklinikken Borgå is presenting the company’s Lenire tinnitus treatment at the Danish Society for Otorhinolaryngology, Head and Neck Surgery (DSOHH) meeting in Nyborg, Denmark. The post notes that attendees are invited to visit a dedicated booth to discuss clinical outcomes, supporting evidence, patient experiences, and potential future cooperation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The content suggests Neuromod is actively deepening its commercial and clinical relationships with ENT specialists in a key European market, which may support wider clinical adoption of Lenire over time. Greater professional engagement and potential new collaborations emerging from events like DSOHH could contribute to expansion of the company’s referral network and revenue opportunities in tinnitus care, while reinforcing its positioning within the neuromodulation and audiology segments.